Poulam M. Patel
Nottingham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 20, 2026
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries.
Journal: Journal for immunotherapy of cancer
Published: March 06, 2026
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
Journal: European urology
Published: December 08, 2025
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
Journal: European urology
Published: December 08, 2025
Modular Supramolecular Polycations Enable Efficient Delivery of Diverse RNA Therapeutics and Vaccines.
Journal: Advanced materials (Deerfield Beach, Fla.)
Published: July 12, 2025
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 22, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2023
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Journal: Nature genetics
Published: August 08, 2023
Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.
Journal: JHEP reports : innovation in hepatology
Published: June 27, 2023
Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Journal: Cancer immunology, immunotherapy : CII
Published: June 07, 2023
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 22, 2023
Last Updated: 09/26/2026